Corcept Therapeutics (CORT) EPS (Basic) (2010 - 2026)

Corcept Therapeutics has disclosed EPS (Basic) across 17 years of filings, most recently posting -$0.3 for Q1 2026.

• EPS (Basic) for Q1 2026 came in at -$0.3, down 257.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.46 (down 63.78% YoY), and the FY2025 annual result was $0.95, down 29.63% from the prior year.
• EPS (Basic) came in at -$0.3 for Q1 2026 at Corcept Therapeutics, down from $0.24 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $0.45 in Q3 2024 to a low of -$0.3 in Q1 2026.
• The 5-year median for EPS (Basic) is $0.27 (2023), against an average of $0.23.
• Across the five-year window, EPS (Basic) soared 100.0% in 2023 and tumbled 257.89% in 2026, its largest moves.
• Corcept Therapeutics' EPS (Basic) stood at $0.15 in 2022, then soared by 100.0% to $0.3 in 2023, then retreated by 3.33% to $0.29 in 2024, then retreated by 17.24% to $0.24 in 2025, then plunged by 225.0% to -$0.3 in 2026.
• The last three EPS (Basic) figures came in at -$0.3 (Q1 2026), $0.24 (Q4 2025), and $0.19 (Q3 2025), per Business Quant data.